

# Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study

William Tillett<sup>1</sup> , Oliver FitzGerald<sup>2</sup> , Laura C. Coates<sup>3</sup> , Jon Packham<sup>4</sup>, Deepak R. Jadon<sup>5</sup> , Marco Massarotti<sup>6</sup> , Mel Brook<sup>7</sup>, Suzanne Lane<sup>8</sup> , Paul Creamer<sup>9</sup>, Anna Antony<sup>10</sup> , Eleanor Korendowych<sup>7</sup>, Adwaye Rambojun<sup>11</sup> , Neil J. McHugh<sup>1</sup> , Philip S. Helliwell<sup>12</sup> ,  
on behalf of the PROMPT Study Group

**ABSTRACT. Objective.** To test shortened versions of the psoriatic arthritis (PsA) composite measures for use in routine clinical practice.

**Methods.** Clinical and patient-reported outcome measures (PROMs) were assessed in patients with PsA at 3 consecutive follow-up visits in a UK multicenter observational study. Shortened versions of the Composite Psoriatic Arthritis Disease Activity Index (CPDAI) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Exercise (GRACE) measures were developed using PROMs and tested against the Disease Activity Score in 28 joints (DAS28), composite Disease Activity in Psoriatic Arthritis, and Routine Assessment of Patient Index Data (RAPID3). Discrimination between disease states and responsiveness were tested with the *t*-score, standardized response mean (SRM), and effect size (ES). Data were presented to members at the GRAPPA 2020 annual meeting and members voted on the recommended composite routine practice.

**Results.** The SRM for the GRACE, 3 visual analog scale (VAS), and 4VAS were 0.67, 0.77, and 0.63, respectively, and for CPDAI and shortened CPDAI (sCPDAI) were 0.54 and 0.55, respectively. Shortened versions of the GRACE increased the *t*-score from 7.8 to 8.7 (3VAS) and 9.0 (4VAS), but reduced the *t*-score in the CPDAI/sCPDAI from 6.8 and 6.1. The 3VAS and 4VAS had superior performance characteristics to the sCPDAI, DAS28, Disease Activity in Psoriatic Arthritis, and RAPID3 in all tests. Of the members, 60% agreed that the VAS scales contained enough information to assess disease and response to treatment, 53% recommended the 4VAS for use in routine care, and 26% the 3VAS, while leaving 21% undecided.

**Conclusion.** Shortening the GRACE to VAS scores alone enhances the ability to detect status and responsiveness and has the best performance characteristics of the tested composite measures. GRAPPA members recommend further testing of the 3VAS and 4VAS in observational and trial datasets.

*Key Indexing Terms:* GRAPPA, outcome measures, psoriatic arthritis

*As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.*

*This report is independent research funded by the National Institute for Health Research (NIHR), Programme Grants for Applied Research (Early detection to improve outcome in patients with undiagnosed PsA [PROMPT], RP-PG-1212-20007). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.*

<sup>1</sup>W. Tillett, BSc, MChB, PhD, FRCP, N.J. McHugh, MChB, MD, FRCP, FRCPATH, Department of Pharmacy and Pharmacology, University of Bath, and Royal National Hospital for Rheumatic Diseases, Bath, UK;

<sup>2</sup>O. FitzGerald, MD, FRCP, FRCP(UK), Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland;

<sup>3</sup>L.C. Coates, MChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; <sup>4</sup>J. Packham, DM, FRCP, Haywood Rheumatology Centre, Stoke-on-Trent, UK; <sup>5</sup>D.R. Jadon, MChB, MRCP, PhD, University of Cambridge, Cambridge, UK; <sup>6</sup>M. Massarotti, MD, Department of

Rheumatology, University Hospitals Dorset NHS Foundation Trust, Christchurch, New Zealand; <sup>7</sup>M. Brook, Patient Research Partner, E. Korendowych, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, Bath, UK; <sup>8</sup>S. Lane, MChB, MD, FRCP, Ipswich Hospital NHS Trust, Ipswich, UK; <sup>9</sup>P. Creamer, MChB, North Bristol NHS Foundation Trust, Bristol, UK; <sup>10</sup>A. Antony, MBBS, School of Clinical Sciences, Monash University, Melbourne, Australia; <sup>11</sup>A. Rambojun, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; <sup>12</sup>P.S. Helliwell, MD, PhD, Professor of Clinical Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, UK.

*SL has received sponsorship for both the European Alliance of Associations for Rheumatology and the American College of Rheumatology this year, both from AbbiVie, and last year for Madrid from Celgene, but no commercial work for any organizations. All other authors declare no conflicts of interest.*

*Address correspondence to Dr. W. Tillett, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Coombe Park, Bath, BA1 3NG, UK. Email: w.tillett@nhs.net.*

Observational studies have demonstrated that psoriatic arthritis (PsA) causes progressive clinical joint destruction, deteriorating functional status, and has a negative effect on the quality of life and ability to work.<sup>1,2</sup> Recent years have seen an increasing number of highly effective therapeutic drug options and a better understanding of how we should use them, including the clinical benefits of applying a treat-to-target strategy.<sup>3</sup> Recently updated PsA treatment guidelines from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) recommend a treat-to-target strategy in clinical practice.<sup>4,5</sup> There is, however, no agreement on how to measure remission/low disease activity in routine practice and feasibility remains a major barrier to wider uptake. Instruments to measure disease need to be easy to perform and calculate in routine clinical practice, and this is a particular challenge in PsA where disease manifestations are varied and assessment of multiple disease manifestations is required to adequately quantify disease. The benefits, limitations, and barriers to wider uptake of composite measures of disease were the subject of a workshop at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting.<sup>6</sup> The majority (89%) of GRAPPA members agreed there was a need for a PsA-specific composite measure for routine practice; however, 62% were either using no measure at all in their practice or were using the Disease Activity Score in 28 joints (DAS28), which was developed for use in rheumatoid arthritis (RA). The members discussed each composite in breakout groups and reported the respective benefits, limitations, and barriers to their wider adoption.<sup>6</sup> The most significant barrier to wider adoption was feasibility. In particular, the Psoriatic Arthritis Disease Activity Score (PASDAS) and the Composite Psoriatic Arthritis Disease Activity Index (CPDAI) were not felt to be feasible in their current form, and the C-reactive protein (CRP) was identified as a barrier to the use of the Disease Activity Score for Psoriatic Arthritis (DAPSA). The members voted to test shortened versions of the CPDAI and the GRAPPA Composite Exercise (GRACE) for use in routine care.<sup>7</sup> We report the testing of shortened versions, comparison with the original versions and other more feasible composite measures such as the DAS28<sup>8</sup> and the routine assessment of the Routine Assessment of Patient Index Data (RAPID3),<sup>9,10</sup> followed by discussion and voting from the composites session at the GRAPPA 2020 annual meeting.

## METHODS

**ASSESS study design.** Details of the ASSESS study design have been previously reported in another article in this supplement.<sup>11</sup> In brief, patients with PsA diagnosed using the CIASsification for Psoriatic ARthritis (CASPAR) criteria<sup>12</sup> were recruited across 6 hospitals in the UK. Participants received routine care from their rheumatologists based on current best practice. Study visits were scheduled at baseline, 3 months, and 6 months. A comprehensive clinical assessment was conducted at each clinical visit, including patient-reported outcome measures (PROMs) and clinical assessments (tender and swollen joint count [66/68], Leeds Enthesitis Index [LEI] and dactylitis count, body surface area of psoriasis (%), Psoriasis Areas and Severity Index [PASI], physician global score [0–5], and CRP) that were sufficient to calculate the composite measures. Patients were classified into 2 groups: (1) those with active disease (requiring a change in treatment),

and (2) patients with low disease activity/remission (who do not require treatment change).

Ethical approval for this study was given by the North East York Research Ethics Committee Ref: 17/NE/0084. All patients signed written consent in accordance with the Declaration of Helsinki.

**Composite measures and modifications.** The CPDAI measures disease activity in 5 domains using 8 measures: peripheral joints (68 tender and 66 swollen joints, and Health Assessment Questionnaire [HAQ]), skin (PASI and Dermatology Life Quality Index), enthesitis (LEI and HAQ), dactylitis (number of tender dactylitic digits and HAQ), and spine (Bath Ankylosing Spondylitis Disease Activity Score [BASDAI] and Ankylosing Spondylitis Quality of Life index). Within each domain, activity is graded as 0 (none), 1 (mild), 2 (moderate), and 3 (severe), according to predefined cutoffs resulting in a score 0–15. The shortened CPDAI (sCPDAI) using 5 measures is reported in Table 1. In brief, the joint domain is assessed with the clinical DAPSA cutoffs, skin using a patient skin visual analog scale (VAS), enthesitis using the LEI, dactylitis using the tender dactylitis count and axial disease using a 0–10 numeric rating scale (NRS) from question 2 of the BASDAI: “How would you describe the overall level of AS neck, back or hip pain you have?”

The GRACE measure is derived from the tender and swollen joint count, HAQ, patient global, skin and joint VAS scores, PASI, and Psoriatic Arthritis Quality of Life. Scores are transformed into linear functions ranging from 0 (totally unacceptable state) to 1 (normal) based on established desirability functions. The 8 transformed variables are then combined using the arithmetic:

$$\text{mean GRACE} = (1 - \text{arithmetic mean of variables}) \times 8$$

Two shortened versions of the GRACE were derived. The physician assessments (joint count and PASI) were reduced to a physician VAS (informed by a full clinical assessment including history and examination) and patient VAS scores for skin, joints, and pain:

- 3VAS: physician global VAS, patient global, and skin VAS
- 4VAS: physician global VAS, patient pain, joint, and skin VAS

Each score is added and divided by the relevant denominator to give a score range 0–10, where 0 is low and 10 is high disease activity.

The RAPID3 (range 0–30) comprises three 0–10 scores: the HAQ–Disability Index (recalculated from 0 to 3), pain VAS, and global VAS.<sup>9</sup> The RAPID3 has been tested in PsA and was correlated significantly with PASDAS in the TICOPA study ( $r = 0.79, P < 0.01$ ) and with DAPSA in the LOPAS II ( $\rho = 0.59, P < 0.01$ ), and was able to discriminate between the treatment arms in the TICOPA study.<sup>10</sup> The composite DAPSA (cDAPSA) is calculated with the addition of the number of painful joints (68), swollen joints (66), patient global VAS, and patient pain VAS.<sup>13,14</sup> The DAS28 is a weighted score that comprises the 28 tender and swollen joint count, patient global VAS, and either CRP or erythrocyte sedimentation rate.<sup>8</sup>

**Table 1.** The shortened CPDAI Score (0–15).

Domain	Scores			
	0	1	2	3
Joints: cDAPSA	≤ 3	4–13	14–27	≥ 28
Skin: skin VAS	< 10	10–29	30–49	≥ 50
Enthesitis: LEI	0	1	2–4	5–6
Dactylitis: count	0	1	2–4	≥ 5
Axial: NRS Q2 BASDAI	0	1–2	3–4	≥ 5

cDAPSA: composite Disease Activity in Psoriatic Arthritis; CPDAI: Composite Psoriatic Arthritis Disease Activity Index; LEI: Leeds Enthesitis Index; NRS Q2 BASDAI: numeric rating scale, question 2 of the Bath Ankylosing Spondylitis Disease Activity Index; VAS: visual analog scale.

The statistical analysis plan for the ASSESS study has been previously reported.<sup>11</sup> In brief, the ability of each measure to detect those patients requiring treatment change was calculated using the independent samples *t*-statistic. Responsiveness of each measure following a change in medication was calculated using the standardized response mean (SRM; the mean difference before and after treatment change divided by the SD of the difference) and magnitude of response using effect size (ES; the mean difference between scores divided by the pooled baseline SD). Test-retest reliability was assessed using the intraclass correlation method and Bland-Altman method.<sup>11</sup>

## RESULTS

**ASSESS study results.** One hundred and thirty-nine patients completed a total of 414 study visits. The mean age of participants was  $52.7 \pm 13.5$  years and mean disease duration of  $6.1 \pm 6.2$  years. The baseline characteristics have been previously reported, but in brief, the mean tender and swollen joint count was  $9.6 \pm 11.8$  and  $3.0 \pm 4.1$ , mean Leeds enthesitis count was  $0.9 \pm 1.5$ , mean Leeds dactylitis count was  $0.3 \pm 0.9$ , mean PASI was  $1.4 \pm 2.0$ , and mean HAQ was  $0.8 \pm 0.7$ .<sup>11</sup>

A full comparison of all the composites and shortened versions are reported in Table 2. The shortening of the CPDAI had a minimal effect on responsiveness. SRM for CPDAI was 0.54 and for sCPDAI was 0.55; however, shortening reduced the ability to detect treatment change (*t*-score fell from 6.8 to 6.1) and the ability to assess magnitude of response, reducing the ES from 0.46 to 0.42, respectively. Shortening the GRACE to the 3VAS improved all the performance characteristics, including SRM (0.67 to 0.77, respectively), *t*-score (7.8 to 8.7, respectively), and ES (0.51 to 0.66, respectively). Shortening of the GRACE to the 4VAS reduced the SRM (0.67 to 0.63) and improved the *t*-score (7.8 to 9.0) and ES (0.51 to 0.55).

**GRAPPA discussion session.** William Tillett introduced the session reviewing the need for a continuous composite measure for use in routine clinical care and the existing candidate measures including the sCPDAI, 3VAS, 4VAS, DAPSA, RAPID3, and DAS28. He reviewed the discussions from the 2019 GRAPPA

Table 2. Composite score responsiveness, magnitude of response, and ability to detect treatment change in 28 patients with psoriatic arthritis.

Composite	SRM	Effect Size	<i>t</i> -score
PASDAS	0.84	0.62	8.3
CPDAI	0.54	0.46	6.8
sCPDAI	0.55	0.42	6.1
GRACE	0.67	0.51	7.8
3VAS	0.77	0.66	8.7
4VAS	0.63	0.55	9.0
cDAPSA	0.59	0.44	5.9
RAPID3	0.5	0.32	7.0
DAS28	0.42	0.47	6.5

cDAPSA: composite Disease Activity in Psoriatic Arthritis; CPDAI: Composite Psoriatic Arthritis Disease Activity Index; DAS28: Disease Activity Score in 28 joints; GRACE: GRAPPA Composite Exercise; GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score; RAPID3: Routine Assessment of Patient Index Data; sCPDAI: shortened CPDAI; SRM: standardized response mean; VAS: visual analog scale.

meeting where members voted on the need for a composite measure for routine practice, the feasibility barriers, and voting to test modifications.

Philip Helliwell reviewed the ASSESS study and the methods used to shorten the CPDAI and GRACE. He described the methods for assessing discrimination (SRM), decision to change treatment (*t*-score), and magnitude of response (ES). He presented the results of the ASSESS study and trial data on the performance characteristics of the CPDAI, sCPDAI, GRACE, 3VAS, 4VAS, cDAPSA, DAS28, and RAPID3.

Comments from the discussion included the following:

- What is it about the construct of the VAS scores that drives the performance characteristics? It is felt likely that the physician VAS contributes significantly to the performance characteristics. Removal of the physician VAS is not reported but reduced the performance of all variables.
- What was the correlation with the PASDAS/GRACE and CPDAI? Although correlations have not been reported, the correlations were all above 0.9 except for the sCPDAI. This is possible because the CPDAI is the only measure that attempts to include assessment of axial symptoms.
- How do we persuade clinicians to do a full clinical assessment with only a physician VAS? Might clinicians not even perform a joint count, let alone other domain measures? There was recognition that this was a potential risk, though possibly no greater than other measures or response criteria (such as the DAS28 or states of low disease activity/remission). There was discussion about the need to educate clinicians on how to assess all domains of disease formally in order to inform an accurate physician VAS.
- Patients commented that the VAS scores were patient-centered with a balance between patient and physician contributions and there was agreement with this approach.
- Could NRS be tested instead of VAS scores in other datasets? The advantages of NRS were recognized and there was agreement that this would be a good analysis to test as well as testing of the 3/4VAS in clinical trial and observational datasets.
- Could we look at the correlation between patient joint VAS and joint count? There was agreement this would be a valuable analysis.
- Should treatment acceptability be included in an assessment tool? This was felt to be important and a complementary component of treatment assessment.

Members went on to vote on the modification of composites for clinical trials; the results are summarized in Table 3. Video links to these sessions are in the Supplementary Material (available with the online version of this article).

## DISCUSSION

We report the performance characteristics of shortened versions of PsA-specific composite measures and comparison with feasible composites developed for the assessment of RA (DAS28 and RAPID3). Modifications to shorten the CPDAI (sCPDAI) did not significantly alter its performance characteristics, while shortening the GRACE to a 3VAS or 4VAS either improved or made little change to its performance characteristics. The overall performance of the 3VAS and 4VAS was superior to the DAS28,

Table 3. Voting results on composite measures for clinical trials in 55 GRAPPA members.

Question	Yes	No	Undecided
Do you agree that VAS scores alone can give sufficient information to assess disease activity and response to treatment?	60%	14%	26%
	4VAS	3VAS	Undecided
Based on the voting at the expert consensus statement and the ASSESS data, would you be happy to recommend 1 of the following VAS scores for use in routine care: 3VAS or 4VAS? (Select any that apply.)	53%	26%	21%

GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; VAS: visual analog scale.

RAPID3, DAPSA, CPDAI/sCPDAI, and in some instances the best performing full composite, the PASDAS.

There are several strengths to the concept of a VAS scale for routine care. Condensing the physician assessment to a VAS frees the clinician to perform the joint count, skin, enthesitis, dactylitis, and axial assessment without the time-consuming need to populate a formula or calculation on paper or computer. Further, a physician VAS allows a clinician to include other less tangible aspects of disease that may not be represented in a joint count or skin assessment such as frequency, duration, intensity of flares, the effect of recent treatment (such as “rescue” glucocorticoids), as well as the patient perspective from the PROMs. It is likely that this increased depth of assessment that a physician VAS permits and its relative contribution to the total score in the VAS scales is responsible for its superior ability to detect treatment change and a magnitude of response comparable to that of the PASDAS.

The decision whether to choose a 3VAS or a 4VAS is challenging. The 4VAS has superior ability to detect treatment change ( $t$ -score) and magnitude of response, but the 3VAS demonstrates better responsiveness using the SRM. From a routine practice perspective, there are advantages in using the 4VAS where patients have an opportunity to represent the 2 cardinal manifestations of PsA, being skin and joint disease, as well as pain, the top-priority outcome from the patient’s perspective. Representation of core outcomes of skin, joints, and pain can inform the emphasis of a consultation in a time-limited consultation, yet still contribute to the composite score to act as a treatment target.

In general, there was support for the VAS measures, but over 70% agreement was not reached in the voting. This was primarily due to the need for more data about cutoffs and comparison of use in clinical/randomized control trial datasets. Some GRAPPA members also discussed the possibility that physicians may try to “cut corners” should a VAS score alone be required instead of a formal assessment of all of the domains of involvement in PsA. It is our view that a physician VAS can only be correctly given following a full disease assessment. We need to make disease assessment as simple and as accessible as possible to facilitate the

adequate assessment of disease in clinical practice. If a clinician is going to “cut corners” with disease assessment when performing a VAS score, they are equally as likely to do this with a more complex score. Although the DAS28 has been included in the analysis reported in this study, it does not have face validity as a composite measure in PsA because it only reflects joint involvement and does not require an assessment of any joints below the knees. We would tentatively propose a tiered system of assessment for clinicians, whereby the 4VAS would be the minimum requirement (informed by a full clinical assessment including history and examination) together with an effect of disease assessment (using the Psoriatic Arthritis Impact of Disease).

There are a number of strengths to this study design. This is an observational study taken from routine care where composites for routine care would normally be used. We chose shortened measures based on a foundation of qualitative work identifying, prioritizing, and ranking outcomes. Shortened measures were then mapped to existing composite measures incorporating discussion and feedback from a global network of clinicians, patient research partners, and industry stakeholders.<sup>6,15,16</sup>

In summary, we report the performance characteristics of shortened continuous composite measures for PsA for use in routine clinical practice. While shortened versions of the CPDAI made little change or reduced its performance characteristics, the shortening of the GRACE measure to the 3VAS or 4VAS scores resulted in superior performance characteristics in terms of ability to detect treatment change, magnitude of change, and responsiveness. The majority of GRAPPA members (60%) voted in favor of the VAS scores, but feedback in the discussion supported the need for further data to support the case for a VAS score composite. This would also inform the decision as to whether to recommend the 3VAS or 4VAS for use in routine clinical practice. Next steps will include the testing of both the 3VAS and 4 VAS scores in clinical trial and observational datasets.

#### ACKNOWLEDGMENT

We would like to thank the patients for their participation in this research project; Sr. Nicola Waldron and Sr. Jan Ball, nurse specialists in PsA;

Sr. Jenny Tyler, Research Nurse; Charlotte Cavill, our database manager; and Mandy Freeth, database administrator.

## ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

## REFERENCES

1. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. *J Rheumatol* 1990;17:809-12.
2. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. *Rheumatol* 2003;42:778-83.
3. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet* 2015;386:2489-98.
4. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis* 2020;79:700-12.
5. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/ National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis Rheumatol* 2019;71:5-32.
6. Tillett W, McHugh N, Orbai AM, Ogdie A, Leung YY, Coates LC, et al. Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership-recommended next steps. *J Rheumatol Suppl* 2020;96:11-8.
7. Tillett W, Adebajo A, Brooke M, Campbell W, Coates LC, FitzGerald O, et al. Patient involvement in outcome measures for psoriatic arthritis. *Current Rheumatol Rep* 2014;16:418.
8. Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. *Br J Rheumatol* 1996;35:1101-5.
9. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. *Rheum Dis Clin North Am* 2009;35:773-8, viii.
10. Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of the Routine Assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. *Arthritis Care Res* 2018;70:1198-205.
11. Tillett W, FitzGerald O, Coates LC, Packham J, Jadon D, Massarotti M, et al. Composite measures for clinical trials in psoriatic arthritis: testing pain and fatigue modifications in a UK multicentre study. *J Rheumatol* 2021;xx:xxxxxx.
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* 2006;54:2665-73.
13. Gonçalves RS, de Almeida Martins LM, de Ataíde Mariz H, Dantas AT, Duarte AL. DAPSA versus cDAPSA: do we need to use CRP? *Ann Rheumatic Dis* 2020;79:e142.
14. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. *Ann Rheum Dis* 2016;75:811-8.
15. Dures E, Hewlett S, Lord J, Bowen C, McHugh N, Group PS, et al. Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. *Patient* 2017;10:455-62.
16. Tillett W, Dures E, Hewlett S, Helliwell P, FitzGerald O, Brooke M, et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. *J Rheumatol* 2017;44:1445-52.